Journal Mobile Options
Table of Contents
Vol. 51, No. 4, 2007
Issue release date: September 2007

Taurine Induces Anti-Anxiety by Activating Strychnine-Sensitive Glycine Receptor in vivo

Zhang C.G. · Kim S.-J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Taurine has a variety of actions in the body such as cardiotonic, host-defensive, radioprotective and glucose-regulatory effects. However, its action in the central nervous system remains to be characterized. In the present study, we tested to see whether taurine exerts anti-anxiety effects and to explore its mechanism of anti-anxiety activity in vivo. The staircase test and elevated plus maze test were performed to test the anti-anxiety action of taurine. Convulsions induced by strychnine, picrotoxin, yohimbine and isoniazid were tested to explore the mechanism of anti-anxiety activity of taurine. The Rotarod test was performed to test muscle relaxant activity and the passive avoidance test was carried out to test memory activity in response to taurine. Taurine (200 mg/kg, p.o.) significantly reduced rearing numbers in the staircase test while it increased the time spent in the open arms as well as the number of entries to the open arms in the elevated plus maze test, suggesting that it has a significant anti-anxiety activity. Taurine’s action could be due to its binding to and activating of strychnine-sensitive glycine receptor in vivo as it inhibited convulsion caused by strychnine; however, it has little effect on picrotoxin-induced convulsion, suggesting its anti-anxiety activity may not be linked to GABA receptor. It did not alter memory function and muscle activity. Taken together, these results suggest that taurine could be beneficial for the control of anxiety in the clinical situations.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Gupta RC, Kim SJ: Role of taurine in organs’ dysfunction and in their alleviation. Crit Care Shock 2003;6:171–175.
  2. Huxtable RJ (ed): The Biochemistry of Sulfur. New York, Plenum Press, 1986.
  3. Huxtable RJ, Barbeau A (eds): Taurine. New York, Raven Press, 1976.
  4. Huxtable RJ: Physiological actions of taurine. Physiol Rev 1992;72:101–163.
  5. Sergeeva OA, Haas HL: Expression and function of glycine receptor in striatal cholinergic interneurons from rat and mouse. Neuroscience 2001;104:1043–1055.
  6. Galarreta M, Bustamanta J, Martin DR: Taurine induces a long-lasting increase of synaptic efficacy and exon excitability in the hippocampus. J Neurosci 1996;16:92–102.
  7. Lombardini JB: High-affinity uptake systems for taurine in tissue slices and central nervous system. Correction of transport data by different experimental procedures. J Neurochem 1977;29:305–312.
  8. Sturman JA: Taurine in development. J Physiol Rev 1993;73:119–147.
  9. Kuriyama K: Taurine as a neuromodulator. Fed Proc 1980;39:2680–2684.
  10. Lin CT, Su YYT, Song GX, Wu JY: Is taurine a neurotransmitter in rabbit retina? Brain Res 1983;337:293–298.

    External Resources

  11. Moran J, Solazar P, Pasantes-Morales H: Effect of tocopherol and taurine on membrane fluidity of retinal rod outer segments. Exp Eye Res 1988;45:769–776.

    External Resources

  12. Birdsall TC: Therapeutic application of taurine. Altern Med Rev 1998;3:128–136.
  13. El Idrissi AE, Messing J, Scalia J, Trenker E: Prevention of epileptic seizures by taurine. Adv Exp Med 2003;526:515–525.
  14. Chen SW, Kong WX, Zhang YJ, Li YL, Mi XJ, Mu XS: Possible anxiolytic effects of taurine in the mouse elevated plus maze. Life Sci 2004;75:1503–1511.
  15. Kong WX, Chen SW, Li YL, Zhang YJ, Wang R, Min L, Mi X: Effects of taurine on rat behaviors in three anxiety models. Pharmacol Biochem Behav 2006;83:271–276.
  16. Simiand J, Keane PE, Morre M: The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology 1984;84:48–53.
  17. Pellow S, Chopin PH, File SE, Briley M: Validation of open:closed entries in an elevated plus maze as a measure of anxiety in the rat. J Neurosci Methods 1985;14:149–167.
  18. Bigler ED: Comparison of effects of bicuculline, strychnine, and picrotoxin with those of pentylenetetrazol on photically evoked afterdischarges. Epilepsia 1977;18:465–470.
  19. Usunoff G, Atsev E, Tchavdarov D: On the mechanism of picrotoxin epileptic seizure (macro- and microelectrode investigations). Electroencephalogr Clin Neurophysiol 1969;27:444–447.
  20. Dunn R, Fielding S: Yohimbine-induced seizures in mice: a model predictive of potential anxiolytic and GABA-mimetic agents. Drug Dev Res 1987;10:177–188.
  21. Costa E, Guidotti A, Mao CC: Evidence for involvement of GABA in the action of benzodiazepines: studies on rat cerebellum; in Costa E, Greengard P (eds): Mechanism of Action of Benzodiazepines. Advances in Biochemical Psychopharmacology. New York, Raven Press, 1975, vol 14, pp 113–151.
  22. Tsuda M, Suzuki T, Misawa M, Nagase H: Involvement of the opioid in the anxiolytic effect of diazepam in mice. Eur J Pharmacol 1996;307:7–14.
  23. Park CR, Seeley RJ, Craft S, Wood SC: Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 2000;68:509–514.
  24. Mohamed AF, Matsumoto K, Tabata K, Takayama H, Kitajima M, Aimi N, Watamabe H: Effects of Uncaria tomentosa total alkaloid and its components on experimental amnesia in mice: elucidation using the passive avoidance test. J Pharm Pharmacol 2000;52:1553–1561.
  25. Huxtable RJ: Taurine in the central nervous sustain and the mammalian actions of taurine CNS. Neurobiology 1989;32:471–533.
  26. Pericic D, Manev H, Bujas M: Gonadal hormones and picrotoxin-induced in male and female rat. Brain Res 1996;14:174–179.

    External Resources

  27. Okamoto K, Kimura H, Sakai Y: Taurine-induced increase of the Cl conductance of cerebellar Purkinje cell dendrites in vitro. Brain Res 1983;259:319–323.
  28. Del Olmo N, Bustamante J, del Rio RM, Solis JM: Taurine activates GABAA but not GABAB receptors in rat hippocampal CA1 area. Brain Res 2000;864:298–307.
  29. White WF, O’Gorman S, Roe AW: The three-dimensional autoradiographic localization of quench-corrected glycine 3H-strychnine as a ligand. J Neurosci 1990;10:795–813.
  30. Lewis CA, Ahmed J, Faber DS: A characterization of glycinergic receptors present in cultured rat medullary neurons. J Neurophysiol 1991;66:1292–1303.
  31. Schmieden V, Kuhse J, Bets H: Agonist pharmacology of neonatal and adult glycine receptor-α subunits: identification of amino acid residues involved in taurine activation. EMBO J 1992;11:2025–2032.
  32. Rajendra S, Vandenberg RJ, Pierce KD: The unique extracellular disulfide loop of the glycine receptor is a principal ligand binding element. EMBO J 1995;14:2987–2998.
  33. Xu H, Wang W, Tang ZQ, Xu TL, Chen L: Taurine acts as a glycine receptor agonist in slices of rat inferior collicus. Hear Res 2006;220:95–105.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50